Centro de Referencia para Lactobacilos (CERELA-CONICET), Chacabuco 145, (T4000ILC) San Miguel de Tucumán, Tucumán, Argentina.
Université Paris-Saclay, INRAE, AgroParisTech, UMR 0496, 78350 Jouy-en-Josas, France.
Gut Microbes. 2022 Jan-Dec;14(1):2110821. doi: 10.1080/19490976.2022.2110821.
There is now strong evidence to support the interest in using lactic acid bacteria (LAB)in particular, strains of lactococci and lactobacilli, as well as bifidobacteria, for the development of new live vectors for human and animal health purposes. LAB are Gram-positive bacteria that have been used for millennia in the production of fermented foods. In addition, numerous studies have shown that genetically modified LAB and bifodobacteria can induce a systemic and mucosal immune response against certain antigens when administered mucosally. They are therefore good candidates for the development of new mucosal delivery strategies and are attractive alternatives to vaccines based on attenuated pathogenic bacteria whose use presents health risks. This article reviews the most recent research and advances in the use of LAB and bifidobacteria as live delivery vectors for human and animal health.
现在有强有力的证据支持使用乳酸菌(LAB)的兴趣,特别是乳球菌和乳杆菌以及双歧杆菌菌株,作为开发用于人类和动物健康目的的新型活体载体。LAB 是革兰氏阳性细菌,已经在发酵食品的生产中使用了数千年。此外,大量研究表明,当经粘膜给予时,遗传修饰的 LAB 和双歧杆菌可以诱导针对某些抗原的全身和粘膜免疫反应。因此,它们是开发新的粘膜传递策略的良好候选物,并且是基于减毒致病性细菌的疫苗的有吸引力的替代品,因为使用减毒致病性细菌会带来健康风险。本文综述了 LAB 和双歧杆菌作为人类和动物健康的活体传递载体的最新研究进展。